cbdMD Statistics
Total Valuation
cbdMD has a market cap or net worth of $2.17 million. The enterprise value is $5.81 million.
| Market Cap | 2.17M |
| Enterprise Value | 5.81M |
Important Dates
The next estimated earnings date is Thursday, August 8, 2024, after market close.
| Earnings Date | Aug 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
cbdMD has 3.87 million shares outstanding. The number of shares has increased by 120.06% in one year.
| Shares Outstanding | 3.87M |
| Shares Change (YoY) | +120.06% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 16.68% |
| Owned by Institutions (%) | 2.89% |
| Float | 3.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 714.29 |
| PS Ratio | 0.10 |
| Forward PS | 0.21 |
| PB Ratio | 0.70 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.07, with a Debt / Equity ratio of 1.86.
| Current Ratio | 1.07 |
| Quick Ratio | 0.43 |
| Debt / Equity | 1.86 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,520.39 |
Financial Efficiency
Return on equity (ROE) is -228.60% and return on invested capital (ROIC) is -222.36%.
| Return on Equity (ROE) | -228.60% |
| Return on Assets (ROA) | -130.20% |
| Return on Capital (ROIC) | -222.36% |
| Revenue Per Employee | $415,039 |
| Profits Per Employee | -$493,354 |
| Employee Count | 52 |
| Asset Turnover | 1.10 |
| Inventory Turnover | 2.02 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -60.84% in the last 52 weeks. The beta is 1.99, so cbdMD's price volatility has been higher than the market average.
| Beta (5Y) | 1.99 |
| 52-Week Price Change | -60.84% |
| 50-Day Moving Average | 0.72 |
| 200-Day Moving Average | 0.80 |
| Relative Strength Index (RSI) | 28.31 |
| Average Volume (20 Days) | 44,155 |
Short Selling Information
The latest short interest is 142,258, so 3.68% of the outstanding shares have been sold short.
| Short Interest | 142,258 |
| Short Previous Month | 157,693 |
| Short % of Shares Out | 3.68% |
| Short % of Float | 4.29% |
| Short Ratio (days to cover) | 2.01 |
Income Statement
In the last 12 months, cbdMD had revenue of $21.58 million and -$25.65 million in losses. Loss per share was -$12.24.
| Revenue | 21.58M |
| Gross Profit | 13.53M |
| Operating Income | -19.66M |
| Pretax Income | -21.65M |
| Net Income | -25.65M |
| EBITDA | -18.76M |
| EBIT | -21.64M |
| Loss Per Share | -$12.24 |
Balance Sheet
The company has $2.11 million in cash and $5.75 million in debt, giving a net cash position of -$3.65 million or -$0.94 per share.
| Cash & Cash Equivalents | 2.11M |
| Total Debt | 5.75M |
| Net Cash | -3.65M |
| Net Cash Per Share | -$0.94 |
| Equity (Book Value) | 3.09M |
| Book Value Per Share | 0.80 |
| Working Capital | 473,690 |
Cash Flow
In the last 12 months, operating cash flow was -$1.31 million and capital expenditures -$402,584, giving a free cash flow of -$1.72 million.
| Operating Cash Flow | -1.31M |
| Capital Expenditures | -402,584 |
| Free Cash Flow | -1.72M |
| FCF Per Share | -$0.58 |
Margins
Gross margin is 62.70%, with operating and profit margins of -91.08% and -118.87%.
| Gross Margin | 62.70% |
| Operating Margin | -91.08% |
| Pretax Margin | -100.33% |
| Profit Margin | -118.87% |
| EBITDA Margin | -86.94% |
| EBIT Margin | -100.26% |
| FCF Margin | -7.95% |
Dividends & Yields
cbdMD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -120.06% |
| Shareholder Yield | -120.06% |
| Earnings Yield | -1,184.04% |
| FCF Yield | -79.23% |
Analyst Forecast
The average price target for cbdMD is $3.00, which is 435.71% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.00 |
| Price Target Difference | 435.71% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on April 25, 2023. It was a reverse split with a ratio of 1:45.
| Last Split Date | Apr 25, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:45 |
Scores
cbdMD has an Altman Z-Score of -20.63 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -20.63 |
| Piotroski F-Score | 2 |